复发多发性骨髓瘤新型风险分层算法的开发与验证
Multiple myeloma (MM) is a malignancy with varying survival outcomes and drivers of disease progression. Existing MM staging tools were developed using data from newly diagnosed patients.…
要点
- RSA可量化总风险、衰弱风险和疾病侵袭性风险。
- 外部验证数据集显示相似的分层效果。
核心结论
- 开发并验证的RSA可将二线多发性骨髓瘤患者分为生存预期显著不同的风险组。
研究设计与样本
- 使用二线治疗的多发性骨髓瘤患者数据开发RSA,并通过Cox模型推导独立预测因素的风险比。
- 采用K自适应分区基于总风险评分进行风险分组,并在外部验证数据集中验证。
主要发现
- 风险组间OS差异显著,相对风险随风险组升高而翻倍。
- 外部验证数据集显示相似的分层效果。
临床怎么用
- 可用于首次复发时评估患者总风险、衰弱风险和疾病侵袭性风险,辅助分层治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple myeloma (MM) is a malignancy with varying survival outcomes and drivers of disease progression. Existing MM staging tools were developed using data from newly diagnosed patients. As patient characteristics and disease-related factors change between diagnosis and the initiation of second-line (2L) treatment, an unmet need exists for a tool that can evaluate risk of death at first relapse. We have developed a risk stratification algorithm (RSA) using data from patients with MM who were at 2L. Hazard ratios for independent predictors of overall survival (OS) were derived from a Cox models, and individual patient scores were calculated for total risk. K-adaptive partitioning for survival was used to stratify patients into groups based on their scores. Relative risk doubled with ascending risk group; median OSs for patients in group 1 (lowest risk)-4 (highest risk) were 61·6, 29·6, 14·2 and 5·9 months, respectively. Differences in OS between risk groups were significant. Similar stratification was observed when the RSA was applied to an external validation data set. In conclusion, we have developed a validated RSA that can quantify total risk, frailty risk and disease aggressiveness risk, and stratify patients with MM at 2L into groups with profoundly different survival expectations.
引用
- Hájek R, Delforge M, Raab MS, et al. Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma. Br J Haematol. 2019. PMID: 31388996. doi:10.1111/bjh.16105
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。